SIMI VALLEY, CA / ACCESSWIRE / August 30, 2019 / Griffin Living is proud to announce Aldi Supermarket’s grand opening in the Griffin Plaza shopping center in Simi Valley, California. The opening is another step in the retail center’s renovation.

The 10.7 acre Griffin Plaza in Simi Valley is at the corner of Tapo Canyon Road and Cochran Street. Calabasas-based Griffin Living started the renovation of the plaza after several years of intense planning. “The existing buildings are being freshened up with a modern design,” says Paul Griffin III, CEO, and President of Griffin Living.

Griffin Plaza will also be the home of a new senior living community that Griffin Living is developing. The idea of housing seniors in a shopping center setting is a paradigm shift in senior living. However, it addresses some of seniors most pressing needs, namely staying connected to their community and being able to walk to places such as a grocery store. Paul Griffin explains, ‘Griffin Living is on the cutting-edge of this concept, and we understand that people want to be involved, and they want the convenience of being close to stores, restaurants, markets, medical facilities and the list goes on and on. It’s just a more convenient lifestyle for them and their loved ones that are visiting.”

CONTACT:
Corporate Headquarters
24005 Ventura Blvd,
Calabasas, CA 91302,
(818) 965-7400

SOURCE: Web Presence

ReleaseID: 558007

NEW YORK, NY / ACCESSWIRE / August 30, 2019 / There are so many forex coaches on the internet who claim their training programs are the best. But if they’re so great, then how come only 10% of forex traders actually make money? You’d think there would be more successful forex traders if all these training programs on the internet were worth anything.

Foreign currency rates are typically never consistent. You could invest in a currency one day, and it’ll drop significantly in value the next day. If you’re a financially conservative person who counts every dollar they spend, then you’re not going to be too successful as a forex trader. All it takes is one trade in the negative zone, and you’ll be quick to cash out and take a loss. That is the worst thing you can do when trading in any financial market, especially forex.

When Hassan Mahmoud first became interested in the forex market, he didn’t want to fall into the same trap as most other traders do. However, his first few trades were based on emotion instead of discipline and strategy. But once he gained more experience at trading currency, he quickly learned how inconsistent the markets truly are. That was when he stopped being so emotional about his trades and started thinking of a more “long-term” strategy for success.

The long-term strategy that Hassan came up with was artificial intelligence. He didn’t want to risk letting his emotions influencing his trades ever again. So, he got together with a group of programmers and developed original A.I. software tools for trading currency on the forex market. These tools evaluate the activity of the market and make trade suggestions on their own. In fact, they can do the trades for you based on certain rules and conditions that you set.

Because of this, you’ll never need to worry about trading emotionally ever again. A.I. doesn’t have any fears or anxieties about losing money as you do. It’ll simply stick to its preprogrammed algorithm for trading currency. Hassan just so happened to program a winning forex formula into his A.I. software. This makes trading currency so much easier for people who’ve never done it before or worry too much.

At 26-years-old, Hassan has been more successful at forex than traders more than double his age. Not only that, but he offers a coaching program to people who want to learn his trading secrets and utilize his software tools. The CEED program features professionals and experts who’ll guide students each week. In some cases, there is a different expert every week. These could be anyone from teachers and coaches to executives in eight-figure companies.

In between the weekly CEED sessions with these experts, students are told to complete workbooks on the material which can be done online or offline. These workbooks prepare students for the topics and strategies being discussed in the next session with an expert. That way, students can come into a session with knowledge on the material already. This will help them better understand the expert and what they’re talking about.

You can join CEED for a low monthly rate. Say goodbye to those so-called forex experts who charge tens of thousands of dollars for subpar training material. Less than $200 per month and one upfront fee of $269 is all you need to the best forex training and mentorship you’ve ever received. You can connect with Hassan and follow him on his mission at https://hassanmahmoud.com/

Contact email: hassanmahmoudbiz@gmail.com

SOURCE: MentionWorth Media

ReleaseID: 556733

NEW YORK, NY / ACCESSWIRE / August 30, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against International Flavors & Fragrances Inc. (“IFF” or “the Company”) (NYSE:IFF) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired IFF securities between May 7, 2018 and August 5, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/iff.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) that Frutarom had bribed customers in Russia and Ukraine; (2) that senior management at Frutarom were aware of such improper payments; (3) that, as a result, Frutarom’s financial results were materially overstated; (4) that, as a result of the improper payments, the Company was reasonably likely to face regulatory scrutiny; (5) that the Company had not completed adequate due diligence before acquiring Frutarom; (6) that, as a result of the foregoing, the Company was unlikely to achieve purported synergies from the acquisition; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 5, 2019, IFF announced its financial results for the second quarter of 2019. IFF significantly lowered its 2019 guidance, advising investors that it expects adjusted earnings per share (“EPS”) of $4.85 to $5.05 on revenue of $5.15 billion to $5.25 billion, down from its previous guidance of adjusted EPS in the range of $4.90 to $5.10 and revenue of $5.2 billion to $5.3 billion. In addition, IFF disclosed that it is investigating improper payments made by two businesses of its Israeli subsidiary Frutarom “operating principally in Russia and Ukraine . . . to representatives of a number of customers.” On this news, IFF’s stock price fell $22.56 per share, or 15.95%, to close at $118.91 per share on August 6, 2019.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/iff. or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss IFF you have until October 11, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557361

NEW YORK, NY / ACCESSWIRE / August 30, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Nektar Therapeutics (NASDAQ:NKTR)
Class Period: February 15, 2019 – August 8, 2019
Deadline: October 18, 2019
For more info: www.bgandg.com/nktr

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) that the Company did not comply with current good manufacturing practices; (2) that, as a result, batches of NKTR-214 were not produced consistently and differed meaningfully; (3) that clinical results from PIVOT-02 differed based on the batch of NKTR-214 used in the study; (4) that, as a result, the PIVOT-02 study did not produce statistically significant results to support a finding of clinical benefit; and (5) as a result, Nektar’s public statements were materially false and misleading at all relevant times.

Pluralsight, Inc. (NASDAQ:PS)
Class Period: August 2, 2018 – July 31, 2019
Deadline: October 15, 2019
For more info: www.bgandg.com/ps

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Pluralsight was experiencing sales execution challenges which impacted its billings; (2) Pluralsight was experiencing substantial delays in hiring and properly training its salesforce that would be necessary to meet its lofty billing projections; (3) Pluralsight was behind on the onboarding of new sales representatives which was causing sales execution issues and preventing the Company from meeting its high growth projections; and (4) as a result, Pluralsight’s public statements were materially false and misleading at all relevant times.

Granite Construction Incorporated (NYSE:GVA)
Class Period: October 26, 2018 – August 1, 2019
Deadline: October 15, 2019
For more info: wwww.bgandg.com/gva

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company had assumed certain risks in connection with its heavy civil joint venture projects bid between 2012 and 2014; (2) there was an “untenable” imbalance of risk sharing between the Company and the joint venture project owners; (3) the Company was reasonably likely to incur additional project costs for its joint venture projects; (4) the Company was reasonably likely to incur additional costs in connection with certain project disputes; and (5) as a result, Granite Construction’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557358

NEW YORK, NY / ACCESSWIRE / August 30, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Verb Technology Company, Inc. (NASDAQ:VERB)
Class Period: January 3, 2018 – May 2, 2018
Deadline: September 9, 2019
For more info: www.bgandg.com/verb

The complaint alleges that on January 3, 2018, Verb revealed a purported agreement with Oracle America, Inc. (the “Oracle Agreement”) and filed Form 8-K with the United States Securities and Exchange Commission omitting the text of the agreement itself. The complaint continues to allege that throughout the Class Period, Verb continued to hype this relationship. During this time, Verb stock price increased over 200% up from $0.12 per share on January 3, 2018 to $2.70 on April 19, 2018.

Reckitt Benckiser Group plc (OTCMKT:RBGLY)
Class Period: July 28, 2014 – April 9, 2019
Deadline: September 16, 2019
For more info: www.bgandg.com/rbgly

The complaint alleges that before and throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose material adverse information. The complaint alleges that Reckitt was involved in a scheme that generated over $3 billion in proceeds enabling opiate abuse among U.S. consumers and mislead investors and the public concerning the health and safety risks of Suboxone Film, its new key opiate product. Specifically, the complaint alleges that Reckitt senior executives planned to switch prescribers from Suboxone Tablets to its Suboxone Film, which had similar active ingredients to Suboxone Tablets, but is dispensed by a thin film placed under the tongue and stored in single-use foil wrappings. In order to prevent generic competition, the company created a marketing campaign to hype the purported safety benefits of Suboxone Film over Suboxone Tablets. The complaint continues to allege that the campaign was fabricating safety concerns of existing treatments, hoping to delay the entry and approval of generics for Suboxone Tablets. As a result, the sales of Suboxone Film grew. From 2010 and 2014, Reckitt revenues from sales of the drug rose to over $840 million annually. As a result of defendants’ false and misleading statements and/or omissions regarding the alleged scheme, Reckitt ADSs traded at artificially inflated prices.

Omnicell, Inc. (NASDAQ:OMCL)
Class Period: October 25, 2018 – July 11, 2019
Deadline: September 16, 2019
For more info: www.bgandg.com/omcl

The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Omnicell recognized revenue for certain transactions before fulfilling its performance obligations; (2) the Company engaged in improper accounting practices to meet revenue targets; (3) the Company experienced weaker demand for new product lines than it had previously projected; (4) consequently, the Company would be required to write-off certain inventory; (5) Omnicell misclassified certain expenses as capitalized expenditures; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557340

NEW YORK, NY / ACCESSWIRE / AUGUST 30, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Abiomed, Inc. (“Abiomed” or the Company”) (NASDAQ: ABMD) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Abiomed securities between January 31, 2019 through July 31, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm’s site:www.bgandg.com/abmd.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) ABIOMED’s revenue growth was in decline; (2) the Company did not have a sufficient plan in place to stem its declining revenue growth; (3) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (4) consequently, ABIOMED was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company’s prior projections and market expectations; and (5) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On August 1, 2019, pre-market, Defendants issued a press release announcing ABIOMED’s financial and operating results for the first quarter of fiscal year 2020 (the “1Q 2020 Press Release”). Among other results, the 1Q 2020 Press Release disclosed ABIOMED’s third consecutive quarter of slowing revenue growth, reporting “first-quarter fiscal 2020 revenue of $207.7 million, an increase of 15.4% compared to revenue of $180.0 million for the same period of fiscal 2019”. This represented a significant decrease in revenue growth from 2Q 2019. Commenting on the Company’s surprising financial result disappointment, the Company’s Chairman, President, and CEO, Defendant Michael R. Minogue (“Minogue”), revealed that the Company’s “new training programs, organizational changes in distribution, and [] external initiatives… will require time to drive more growth in the future”.

The Company also slashed its previously issued full-year 2020 guidance from total revenues in the range of $900-945 million to total revenues in the range of $885-925 million, which fell roughly $22 million short of market expectations.

Following the Company’s disclosure of its 1Q 2020 financial performance and revised guidance, Investor’s Business Daily published an article raising concern with Defendant Minogue’s prior public statements, titled: “This Medtech’s CEO Promised To ‘Correct The Course’ – That Didn’t Happen”.

On this news, ABIOMED’s stock price fell $73.69 per share, or 26.45%, to close at $204.87 per share on August 1, 2019.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/abmd or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Abiomed you have until October 7, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE:Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557979

NEW YORK, NY / ACCESSWIRE / August 30, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

3M Company (NYSE:MMM)
Class Period: February 9, 2017 to May 28, 2019
Lead Plaintiff Deadline: September 27, 2019

During the class period, 3M Company allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) 3M had vast internal evidence dating back decades confirming that polyfluoroalkyl substances (“PFAS”) are toxic (which was first publicly revealed in February 2018 by Minnesota’s Attorney General); (ii) 3M had a decades-long history of suppressing negative information and/or damaging data about PFAS; and (iii) 3M has legal exposure to state, county, and local governments and individuals around the country as a result of its knowledge and intentional concealment of the toxic harm caused by the use of PFAS.

Learn about your recoverable losses in MMM: http://www.kleinstocklaw.com/pslra-1/3m-company-loss-submission-form?id=3271&from=1

Eagle Bancorp, Inc. (NASDAQ:EGBN)
Class Period: March 2, 2015 to July 17, 2019
Lead Plaintiff Deadline: September 23, 2019

Eagle Bancorp, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Eagle Bancorp’s internal controls and procedures and compliance policies were inadequate; (ii) the foregoing shortcoming created a foreseeable risk of heightened regulatory scrutiny and the need for the Company undertake its own internal investigations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in EGBN: http://www.kleinstocklaw.com/pslra-1/eagle-bancorp-inc-loss-submission-form?id=3271&from=1

Valaris plc (NYSE:VAL)
Class Period: April 11, 2019 to July 31, 2019
Lead Plaintiff Deadline: October 21, 2019

The complaint alleges that during the class period Valaris plc made materially false and/or misleading statements and/or failed to disclose that: (i) the Company was plagued by a weak ultra-deepwater segment, massive cash usage, and significant negative cash flow; (ii) the foregoing was reasonably likely to have a material negative impact on the Company’s second quarter 2019 results; (iii) the merger leading to Valaris’s establishment could not deliver on its touted benefits; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in VAL: http://www.kleinstocklaw.com/pslra-1/valaris-plc-loss-submission-form?id=3271&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 558004

NEW YORK, NY / ACCESSWIRE / August 30, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

Karyopharm Therapeutics Inc (NASDAQGS:KPTI)

Lawsuit on behalf of: investors who purchased on behalf of shareholders of Karyopharm Therapeutics Inc. who: (1) purchased shares of Karyopharm’s common stock between March 2, 2017 and February 22, 2019, inclusive; (2) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around April 28, 2017; or (3) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around May 7, 2018.
Lead Plaintiff Deadline : September 23, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/karyopharm-therapeutics-inc-loss-form?prid=3270&wire=1

According to the filed complaint, Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.

National General Holdings Corp. (NASDAQ:NGHC)

Lawsuit on behalf of: investors who purchased August 6, 2015 – August 9, 2017
Lead Plaintiff Deadline : September 23, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/national-general-holdings-corp-loss-form?prid=3270&wire=1

According to the filed complaint, during the class period, National General Holdings Corp. made materially false and/or misleading statements and/or failed to disclose that: (a) National General was perpetrating a massive forced-placed CPI scheme to fraudulently saddle its own customers with unwanted and unneeded automobile insurance policies that it had underwritten; (b) National General’s illicit conduct in foisting unwanted and unneeded automobile insurance on its customers had resulted in some of the victims being declared delinquent, suffering adverse impacts to their creditworthiness, and/or having their cars improperly repossessed; (c) National General was exposed to an extreme risk of regulatory scrutiny, legal risks, and reputational harm as a result of its participation in the forced placed CPI scheme; (d) the Company had failed to maintain effective internal controls over its financial reporting, including by failing to maintain formal documentation sufficient to reasonably ensure the accuracy of internal reporting and accounting procedures across much of its business, including with respect to insurance policy premiums; (e) the Company’s reported quarterly revenues and policy premiums were in part the product of a fraudulent forced-placed insurance scheme and were therefore artificially inflated and unsustainable; and (f) National General had in fact lost substantial business with Wells Fargo because Wells Fargo had terminated the forced-placed CPI scheme after concluding that it posed excessive reputational risk and legal exposure.

Mallinckrodt Public Limited Company (NYSE:MNK)

Lawsuit on behalf of: investors who purchased February 28, 2018 – July 16, 2019
Lead Plaintiff Deadline : September 24, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/mallinckrodt-public-limited-company-loss-form?prid=3270&wire=1

According to the filed complaint, during the class period, Mallinckrodt Public Limited Company made materially false and/or misleading statements and/or failed to disclose that: (i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 558001

RIVERSIDE, CA / ACCESSWIRE / August 30, 2019 / Eliseo Delgado’s online readers consist of professionals and consumers looking to receive insightful reviews of new products and technologies. To help inform readers of trending topics in gaming news, he leads a discussion on Intel’s plan-in-the-works to begin offering new GPU models for computer gamers.

Eliseo Delgado Jr. has shared updates and complex tech topics in layman’s terms for his online readers since graduating from The New York University Tandon School of Engineering in 2009. Working as a professional computer engineer, he’s researched, designed, developed, and tested computer systems and components such as processors, circuit boards, memory devices, networks, and routers. As a writer and reviewer, he’s become an authoritative voice on topics like artificial intelligence, cryptocurrency, and the Internet of Things (IoT).

He’s closely followed the media rumors and announcements from Intel surrounding their release of a new GPU for gamers, and he helps readers understand more about what’s going on below.

“The news that Intel plans on releasing their own GPU for gamers is a pretty big deal since the market is already dominated by a couple major manufacturers,” says Eliseo Delgado Jr. “It has a lot of people wondering whether the company’s made a tremendous mistake or an insanely lucrative investment–because it’s an expensive undertaking.”

GPU vs CPU

The central processing unit (CPU) of any computer works like a brain and a powerhouse for the machine’s various functions. This main processor carries out instructions from computer programs through electronic circuits.

“The CPU can perform a range of tasks that make complex computer commands possible, and every computer needs one,” says Eliseo Delgado Jr.

Computer gamers rely heavily on graphic processing units (GPU) as they render the display images from computers to the monitors. It’s a specialized circuit that creates images in a frame buffer that is then sent to whatever screen or display the computer is connected to. The more powerful the GPU, the better the graphics and the frame speed associated with them. Graphic processing units are present in many consumer electronics today (such as mobile phones and personal computers), and they are essential in gaming.

Intel’s Announcements

In January, the Senior VP of Client Computing told the crowd attending CES that they will produce a new GPU that would be manufactured on Intel’s 10nm process. In March, the company presented two designs for their GPU while on stage. And in May, the director of the rendering and visualization team and senior principal engineer announced the Xe’s ray tracing capabilities during FMX19 to much excitement.

“The market has been dominated by a pair of companies for decades, so Intel’s attempt to jump in the market is definitely surprising, and many people doubt they will have a lasting impact,” says Eliseo Delgado . “But while the hurdle is enormous, Intel is a highly-reputable company with plenty of funds and connections, so they just might produce something game-changing for gamers.”

CONTACT:
Caroline Hunter
Web Presence, LLC
+1 7862338220

SOURCE: Web Presence, LLC

ReleaseID: 558000

NEW YORK, NY / ACCESSWIRE / August 30, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Ideanomics Inc. (NASDAQ:IDEX)
Class Period: May 15, 2017 – November 13, 2018,
Deadline: September 17, 2019
For more info: www.bgandg.com/idex

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) costs associated with building out Ideanomics’ U.S. infrastructure and hiring its new executive team were negatively impacting the Company’s bottom line performance; (2) as a result, Ideanomics was highly unlikely to meet its 2018 EBITDA guidance; (3) Ideanomics’ margins in its oil trading and consumer electronics businesses were too low for those businesses to remain viable; and (4) as a result, Ideanomics’ public statements were materially false and misleading at all relevant times.

Netflix, Inc. (NASDAQ:NFLX)
Class Period: April 17, 2019 – July 17, 2019
Deadline: September 20, 2019
For more info: www.bgandg.com/nflx

The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Netflix would not be able to gain its expected target number of new subscribers in the second quarter of 2019; (2) Netflix would also lose subscribers from the United States in the second quarter of 2019; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557355